HBV感染母亲新生儿预防接种与母乳喂养*

doi:10.3969/j.issn.1672-5069.2019.01.003

Abstract

Wang Rongming, Jiang Jianning.. Evaluation of breastfeeding and neonatal immune inoculation in mother with HBV infection[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 6-8.

[1] World Health Organization.Guidelines for the prevention,care and treatment of persons with chronic hepatitis B infection. World Health Organization,2015.
[2] Singh AE,Plitt SS,Osiowy C,et al.Factors associated with vaccine failure and vertical transmission of hepatitis B among a cohort of Canadian mothers and infants. J Viral Hepat,2011,34(7):S19-S20.
[3] Han GR,Cao MK,Zhao W,et al.A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol,2011,55:1215-1221.
[4] Tran TT.Management of hepatitis B in pregnancy:weighing the options. Cleve Clin J Med,2009,76(Suppl 3):S25.
[5] Han L,Zhang HW,Xie JX,et al.A Meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World J Gastroenterol,2011,17(38):4321-4333.
[6] Pol S,Corouge M,Fontaine H.Hepatitis B virus infection and pregnancy. Clin Res Hepatol Gastroenterol,2011,35(10):618-622.
[7] Chen X,Chen J,Wen J,et al.Breastfeeding is not a risk factor for mother-to-child transmission of hepatitis B virus. Plos One,2013,8(1):e55303.
[8] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-Ⅴ-ⅩⅩⅢ.
[9] Sarin SK,Kumar M,Lau GK,et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int,2016,10(1):1-98.
[10] Lampertico P,Agarwal K,Berg T,et al.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398.
[11] Terrault NA,Lok AS,Mcmahon BJ,et al.Update on prevention,diagnosis,and treatment and of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology,2018,67(4):1560-1599.
[12] Chen H,Lee C,Chang C,et al.Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology,2015,62(2):375-386.
[13] Greenup AJ,Tan PK,Nguyen V,et al.Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol,2014,61(3):502-507.
[14] Pan CQ,Duan Z,Dai E,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med,2016,374(24):2324-2334.
[15] 吴晓莉,江建宁,苏明华,等. 核苷(酸)类似物阻断HBV母婴传播的效果及安全性. 山东医药,2015,23(6):21-23.
[16] Ehrhardt S,Xie C,Guo N,et al.Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis,2015,60(2):275-278.
[17] Nguyen V,Tan PK,Greenup AJ,et al.Anti-viral therapy for prevention of perinatal HBV transmission:extending therapy beyond birth does not protect against post-partum flare. Aliment Pharmacol Ther,2014,39(10):1225-1234.
[18] Wen WH,Huang CW,Chie WC,et al.Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection. Hepatology,2016,64(5):1451-1461.
[19] Mirochnick M,Taha T,Kreitchmann R,et al.Pharmacokinetics and safety of tenofovir in HIV-infected women during labor and their infants during the first week of life. J Acquir Immune Defic Syndr,2014,65(1):33-41.
[20] Jao J,Abrams EJ,Phillips T,et al.In utero tenofovir exposure is not associated with fetal long bone growth. Clin Infect Dis,2016,15(12):1604-1609.
[21] Siberry GK,Jacobson DL,Kalkwarf HJ,et al.Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate during pregnancy. Clin Infect Dis,2015,61(6):996-1003.
[22] Jacobson DL,Patel K,Williams PL,et al.Growth at 2 years of age in HIV-exposed uninfected children in the United States by trimester of maternal antiretroviral initiation. Pediatr Infect Dis,2017,36(2):189-197.
[23] Hu Y,Wu Q,Xu B,et al.Influence of maternal antibody against hepatitis B surface antigen on active immune response to hepatitis B vaccine in infants. Vaccine,2008,26(48):6064-6067.
[24] Bruce MG,Bruden D,Hurlburt D,et al.Antibody levels and protection after hepatitis B vaccine:Results of a 30-year follow-up study and response to a booster dose. J Infect Dis,2016,214(1):16-22.
[25] Zou H,Chen Y,Duan Z,et al.Protective effect of hepatitis B vaccine combined with two-dose hepatitis B immunoglobulin on infants born to HBsAg-positive mothers. Plos One,2011,6(10):e26748.
[26] Chen HL,Lin LH,Hu FC,et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology,2012,142(4):773-781.e2.

Evaluation of breastfeeding and neonatal immune inoculation in mother with HBV infection

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[8]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[9]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[10]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[11]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[12]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[13]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[14]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[15]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.